Pfizer shelves obesity pill plan after patient suffers liver injury during clinical trial
Pfizer Inc. has said it will discontinue development of its closely watched obesity pill, danuglipron, dealing a severe blow to the company’s ambitions to compete in the rapidly growing weight-lo…